Thyroid Cancer
Conditions
Keywords
Anlotinib, Iodine
Brief summary
The purpose of this study is to assess the efficacy and safety of anlotinib in combination with I-131 in locally advanced/metastatic differentiated thyroid cancer. Anlotinib may stop the growth of tumor cells and improve iodine uptake.
Detailed description
Primary Outcome Measures: objective response rate (ORR) Secondary Outcome Measures： 1. Biochemical Response Rate (BRR) Biochemical response rate is defined as the percentage of subjects whose Tg was consecutive decreases more than 25% compared to baseline twice 2. Disease Control Rate (DCR) 3. Progression-free Survival (PFS) (median) was determined using the number of months measured from the initial date of treatment to the date of documented progression, or the date of death (in the absence of progression) of participants. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. 4. Nuclear medicine functional imaging changes of target lesions The dynamic changes of I uptake and 18F-FDG PET/CT imaging
Interventions
DRUGAnlotinib hydrochloride
Anlotinib hydrochloride may stop the growth of tumor cells and improve iodine uptake.
DRUGSodium Iodide I 131
RAI treatment may shrink the tumor
DRUGPenpulimab
Penpulimab is a novel structure Immune checkpoint inhibitor. The combination of Penpulimab and RAI might have synergistic effects for DTC.
Sponsors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Peking Union Medical College Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* local advanced or metastatic differentiated thyroid cancer (DTC) * scheduled to receive RAI treatment. * absence of good remission of RAI or may not get satisfactory remission from RAI treatment * At least one measurable lesion, with diameter ≥ 10mm measured by spiral MRI/CT scan per RECIST1.1. * Be 18 years of age or older, ECOG PS: 0-2. Life expectancy of at least 6 months. * Main organs function is normal. * The woman patients of childbearing age who must agree to take contraceptive methods (e.g. intrauterine device, contraceptive pill or condom) during the research and within another 6 months after it; who are not in the lactation period and examined as negative in blood serum test or urine pregnancy test within 7 days before the research; The man patients who must agree to take contraceptive methods during the research and within another 6 months after it.
Exclusion criteria
* Patients who had previously received treatment with Antiangiogenic tyrosine kinase inhibitors, such as: Anlotinib, apatinib and Lenvatinib. * Patients who had previously received local treatment within 4 weeks or Participated in other anti-tumor clinical trials within 4 weeks. * Patients with previous or current concurrent malignancies or solid organs or bone marrow transplants within 5 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy * Unmitigated ≥ grade 2 toxicity (CTC AE 5.0) due to any prior treatment, excluding alopecia. * With kinds of factors which affect oral medicine (e.g. failing to swallow, gastrointestinal tract getting resected, chronic diarrhea and ileus) * Patients with pleural effusion or ascites. * Patients with any severe and/or uncontrolled disease. * Patients who underwent major surgery, open biopsy or significant traumatic injury within 4 weeks. * Regardless of the severity, patients with any physical signs or history of bleeding, patients with bleeding or bleeding events greater than or equal to CTCAE 2 within four weeks prior to the first administration, or patients with unhealed wounds, fractures, ulcers. * Patients with arterial or venous thromboembolic events occurred within 6 months, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis and pulmonary embolism.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| objective response rate (ORR) | up to 24 months | Proportion of patients with target lesions reaching PR or CR |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease Control Rate (DCR) | up to 24 months | Proportion of patients with target lesions reaching PR, CR or SD |
| Biochemical Response Rate (BRR) | up to 24 months | Biochemical response rate is defined as the percentage of subjects whose Tg was consecutive decreases more than 25% compared to baseline twice |
| Progression-free Survival (PFS) (median) | up to 24 months | PFS was determined using the number of months measured from the initial date of treatment to the date of documented progression, or the date of death (in the absence of progression) of participants. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions |
| Nuclear medicine functional imaging changes of target lesions | up to 24 months | The dynamic changes of I uptake and 18F-FDG PET/CT imaging |
Countries
China
Contacts
Primary ContactYansong Lin, MD
Outcome results
None listed